Current status of calcium channel blockers in patients with cardiovascular disease

Current Problems in Cardiology

Volumn 24, Issue 5, 1999, Pages 233-340

  Freher, Mark ^a   Challapalli, Sridevi ^a   Pinto, Jack V ^a   Schwartz, Janice ^a   Bonow, Robert O ^a   Gheorgiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMLODIPINE; AMLODIPINE BESYLATE; ATENOLOL; BENZOTHIAZEPINE DERIVATIVE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FIBRINOLYTIC AGENT; HYDROCHLOROTHIAZIDE; ISRADIPINE; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRATE; PHENYLALKYLAMINE; PRAZOSIN; PROPRANOLOL; UNINDEXED DRUG; VERAPAMIL;

ACUTE HEART INFARCTION; ANGINA PECTORIS; CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG STRUCTURE; DRUG UTILIZATION; ENDOVASCULAR SURGERY; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART VENTRICLE FUNCTION; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; REVIEW; SECONDARY PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HEMODYNAMICS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CARDIOVASCULAR DISEASES; HEMODYNAMIC PROCESSES; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0033128361     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0146-2806(99)90000-2     Document Type: Review

References (335)

1. Triggle DJ. Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefridil, a new calcium channel antagonist. Am J Cardiol 1996;78(suppl A):7-12.
2. Katz A. Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol 1996;28:522-9.
3. Triggle DJ. Calcium antagonists. In: Antonaco M, editor. Cardiovascular pharmacology. 3rd ed. New York: Raven Press; 1990. p. 107-14.
4. Nargeot J, Lory P, Richard S. Molecular basis of the diversity of calcium channels in cardiovascular tissues. Eur Heart J 1997;18(suppl A):A15-A26.
5. Hermsmeyer K. Role of T channels in cardiovascular function. Cardiology 1998;89(suppl 1):2-9.
6. Hermsmeyer K, Mishra S, Miyagawa K, et al. Physiologic and pathophysiologic relevance of T-type calcium ion channels: potential indications for calcium antagonists. Clin Ther 1997;19(suppl A);18-26.
7. Triggle DJ. Calcium channel antagonists: mechanisms of action, vascular selectives, and clinical relevance. Cleve Clin J Med 1992;59:617-27.
8. Pitt B. Diversity of calcium antagonists. Clin Ther 1997;19(suppl A):3-7.
9. Piepho RW. Calcium antagonist in patients with congestive heart failure: still a bridge too far. J Clin Pharmacol 1995;35:443-53.
10. Raspa RF, Wilson CC. Calcium channel blockers in the treatment of hypertension. Am Fam Physician 1993;48:461-70.
11. Anonymous. Roche, FDA announce new drug-interaction warnings for mibefridil. American Journal of Health-System Pharmacy 1998;55:210.
12. Schassmann-Suhijar D, Bullingham R, Gasser R, et al. Rhabdomyolysis due to interaction of simvastatin with mibefridil. Lancet 1998;351:1929-30.
13. Opie LH. Mechanisms whereby calcium channel antagonists may protect patients with coronary artery disease. Eur Heart J 1997;18:A92-A104.
14. Thaulow E, Guth BD, Ross J. Role of calcium channel blockers in experimental exercise induced ischemia. Cardiovasc Drugs Ther 1987;1:503-12.
15. Lichtien PR, Engel HJ, Raffenbeul W. Calcium entry blockers especially nifedipine in angina of effort: possible mechanisms and clinical implications. In: Opie LH, editor. calcium antagonists and cardiovascular disease. New York: Raven Press; 1984. p. 221-36.
16. Gage JE, Hess OM, Murakami T, et al. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986;73:865-76.
17. Benhorin J, Banai S, Morel M, et al. Circadian variations in ischemic threshold and relation to the occurrence of ischemic episodes. Circulation 1993;87:808-14.
18. Gunther S, Muller JE, Mudge GH, et al. Therapy of coronary vasoconstriction in patients with coronary artery disease. Am J Cardiol 1981;47:157-62.
19. Ardissimo D, DeServi S, Barberis P, et al. Significance of hyperventilation induced ST segment depression in patients with coronary artery disease. J Am Coll Cardiol 1989;13:804-10.
20. Opie LH. Calcium channel antagonists in management of anginal syndromes: changing concepts in relation to the role of coronary spasm. Prog Cardiovasc Dis 1996;36:291-314.
21. Henry PD. Atherogenesis, calcium and calcium antagonists. Am J Cardiol 1990;66:3I-7I.
22. Rafflenbeul W. Antiatherosclerotic properties of nifedipine. Benefit of early intervention to prevent cardiovascular complications. Cardiology 1997;88(suppl 3):52-5.
23. Catapona A. Calcium antagonists and atherosclerosis: experimental evidence. Eur Heart J 1997;18:A80-A86.
24. Loaldi A, Polese A, Montorsi P, et al. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary artery narrowings in angina pectoris. Am J Cardiol 1989;64:433-9.
25. Lichtien PR, Hugenholtz PG, Raffenbeul W, et al. Retardation of coronary artery disease in man by the calcium channel blocker nifedipine Results of the INTACT trial. Lancet 1990;335:1109-13.
26. Waters D, Lesperance J, Franetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;82;1109-13.
27. Gottlieb SO, Brinker JA, Mellits DE, et al. Circulation 1989;80(suppl II):228.
28. Zanchetti A, Mangani B, Dal Palu C, et al. Atherosclerosis and calcium antagonists: the VHAS study. J Hum Hypertens 1992;6(suppl 2):S45-48.
29. Hjemdahl PH, Wallen NH. Calcium antagonist treatment, sympathetic activity and platelet function. Eur Heart J 1997;18(suppl A):A36-A50.
30. Wallen NH, Held C, Rehnquist N, et al. Platelet aggregability in vivo is attenuated by verapamil but not metoprolol in patients with stable angina pectoris. Am J Cardiol 1995;75:1-6.
31. Weiss K, Fitscha P, Virgolini I, et al. Influence of a single dose of calcium channel blockers in platelet function. Platelets 1991;2:41-3.
32. Kristensen SD, Schmidt EB, Dyerberg J. Verapamil does not alter platelet function in patients with recent myocardial infarction. Thromb Res 1983;32:437-42.
33. Gore JM, Sloan M, Price M, et al. Intracerebral hemorrhage, cerebral infarction and subdural hematoma after acute myocardial infarction and thrombolytic therapy in TIMI II pilot and clinical trial. Circulation 1991;83:448-59.
34. Wagenknecht L, Furberg CD, Hammon JW, et al. Surgical bleeding: an unexpected effect of a calcium antagonist. BMJ 1995;310:776-7.
35. Zernig G. Widening potential for calcium antagonists: non L type calcium channel interactions. Trends Pharmacol Sci 1990;11:38-44.
36. Murphy JG, Marsh JD, Smith TW. The role of calcium in ischemic myocardial injury. Circulation 1987;75(suppl v):v15-v24.
37. Nayler WG, Ferrari R, Williams A, et al. Protective effects of pretreatment with verapamil, nifedipine, and propranalol on mitochondrial function in the ischemic and reperfused myocardium. Am J Cardiol 1980;46:242-8.
38. Nayler WG, Panagiotopoulos S, Elz J, et al. Fundamental mechanism of action of calcium antagonists in myocardial ischemia. Am J Cardiol 1987;59:75B-83B.
39. Michalewics L, Fesserli F. Cardiac effects of calcium antagonists in systemic hypertension. Am J Cardiol 1997;79:39-46.
40. Vogt M, Strauer BE. Response of hypertensive left ventricular hypertrophy and microvascular disease to calcium antagonists. Am J Cardiol 1995;76:24D-30D.
41. Cruickshank JM, Lewis J, Moore V, et al. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;6:85-90.
42. Schmieder RE, Martus P, Kleingreil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta analysis of randomized double blind studies. JAMA 1996;275:1507-13.
43. Wachter RM. Symptomatic hypotension induced by nifedipine in the acute treatment of severe hypertension. Arch Intern Med 1987;147:556-8.
44. Grossman E, Messerli F, Godzicki T, et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies. JAMA 1996;276:1328-31.
45. Phillips RA, Goldman ME, Ardeljan M, et al. Isolated T wave abnormalities and evaluation of left ventricular wall motion after nifedipine given for severe hypertension. Am J Hypertens 1991;4:432-7.
46. Ergstrup K, Anderson PE. Transient myocardial ischemia during nifedipine therapy in stable angina and its relation to coronary blood flow compared to metoprolol. Am J Cardiol 1993;71:177-83.
47. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers for the onset of acute cardiovascular disease. Circulation 1989;179:733-43.
48. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate and blood pressure. Am J Cardiol 1997,80:1453-58.
49. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection and Treatment of High Blood Pressure. Arch Intern Med 1993;153:154-83.
50. Rosei EA, Dal Palu C, Leonetti G, et al. Clinical results of the verapamil in hypertension and atherosclerosis study. VHAS Investigators. J Hypertens 1997;15:1337-44.
51. Rosito GA, Gebara OC, McKenna CA, et al. Effect of sustained release verapamil on the morning systemic arterial pressure surge during daily activity in patients with systemic hypertension. Am J Cardiol 1997;79:1252-5.
52. Materson BJ, Redda DJ, Cushman WC, et al. Single drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-21.
53. Hornung RS, Gould BA, Jones RI, et al. Nifedipine tablets for systemic hypertension: a study using continuous ambulatory intraarterial recording. Am J Cardiol 1983;51:1323-27.
54. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study. JAMA 1993:270:713-724.
55. Oparil S, Bernink P, Bursztyn M, et al. Antihypertensive effects of mibefradil in the treatment of mild to moderate systemic hypertension. Am J Cardiol 1997; 80:12C-19C.
56. Psaty B, Heckbert S, Koepsell T, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
57. Jick H, Derby L, Gurewuch V, et al. The risk of myocardial infarction in persons with uncomplicated essential hypertension associated with antihypertensive drug treatment. Pharmacotherapy 1996;16:321-6.
58. Aursenes I, Litleskare I, Froyland H, et al. Association between various drugs used for hypertension and risk of acute myocardial infarction. Blood Press 1995; 4:157-63.
59. Pahor M, Gurahik J, Corti M, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:1-7.
60. Abascal V, Larson M, Evans J, et al. Calcium antagonists and mortality risk in men and women with hypertension: the Framingham Heart Study. Arch Intern Med 1998;158:1882-6.
61. Braun S, Boyko V, Behar S, et al. Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients. J Am Coll Cardiol 1996;28:7-11.
62. Epstein M. Calcium channel blockers and hypertension: 2. safety issues. Hosp Pract 1996;31:99-104.
63. Borhani M, Mercuri M, Borhani PA, et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA 1996;276:785-91.
64. Estacio R, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with noninsulin dependent diabetes and hypertension (ABCD Trial). N Engl J Med 1998;3387:645-52.
65. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:655-7.
66. Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996;14:1237-45.
67. Staessen J, Fagard R, Thijs L, et al. Randomized double blind comparison of placebo and active treatment of older patients with isolated systolic hypertension. Lancet 1997;350:757-62.
68. The Glant Study Group. A 12-month comparison of ACE inhibitor and calcium antagonist therapy in mild to moderate essential hypertension - the GLANT study. Hypertens Res 1995;18:235-44.
69. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin treatment in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. The HOT study group. Lancet 1998;351:1748-9.
70. Schwartz JB. Calcium antagonists in the elderly: a risk benefit analysis. Drugs Aging 1996;1:24-36.
71. Brown M, Castigne A, Ruilope LM, et al. International nifedipine GITS study intervention as goal in hypertension treatment. J Hum Hypertens 1996;10(suppl 3):S157-60.
72. The Nordil Group, the Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Press 1993; 2:312-21.
73. Malacco E, Gnemmi AE, Romagnoli A, et al. Systolic hypertension in the elderly. Long-term lacidipine treatment (SHELL). J Cardiovasc Pharmacol 1994;23(suppl 5):S62-S66.
74. Dahlof B, Hansson L, Lindholm L, et al. STOP-Hypertension 2: a prospective intervention trial of newer versus older treatment alternatives in old patients with hypertension. Blood Press 1993;2:136-141.
75. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am J Hypertens 1996;9:342-60.
76. Nayler WG, Panagiotopoulos S, Elz JS, et al. Fundamental mechanisms of action of calcium antagonists in myocardial ischemia. Am J Cardiol 1987;59:75B-83B.
77. Kloner RA, Braunwald E. Effects of calcium antagonists on infarcting myocardium. Am J Cardiol 1987;59:84B-94B.
78. Braunwald E, Jones RH, Mark DB, et al. Diagnosing and managing unstable angina. Circulation 1994;90:613-22.
79. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both? To treat acute unstable angina. N Engl J Med 1988;319:1105-11.
80. Gerstenblith G, Ouyang P, Achugg S, et al. Nifedipine in unstable angina: a double blind randomized trial. N Engl J Med 1982;306:885-9.
81. Muller JE, Turi ZG, Pearle DL, et al. Nifedipine and conventional therapy for unstable angina pectoris: a randomized, double blind comparison. Circulation 1984;69:728-39.
82. Report of the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomized, double blind, placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986;56:403-10.
83. Gobel EJ, Hautvast RW, Van Gust WH, et al. Randomised, double blind trial of intravenous diltiazem versus glycerol trinitrate for unstable angina pectoris. Lancet 1995;346:1653-7.
84. Andre-fouet X, Usdin JP, Gayet C, et al. Comparison of short term efficacy of diltiazem versus propranolol in unstable angina at rest: a randomized trial of 70 patients. Eur Heart J 1983;4:691-8.
85. Theroux P, Taeymans Y, Morissette D, et al. A randomised study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol 1985;5:717-22.
86. Hennekens CH, Alpert CM, Godfried SL, et al. Adjunctive therapy of acute myocardial infarction - evidence from clinical trials. N Engl J Med 1996; 335:1660-7.
87. Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomised, double blind, placebo controlled comparison. Circulation 1984;69:740-7.
88. Sirnes PA, Overskied K, Pedersen TR, et al. Evolution of infarct size during early use of nifedipine in patients with acute myocardial infarction: the Norwegian Multicenter Trial. Circulation 1984;70:638-44.
89. Wilcox RG, Hampton JR, Banks BC, et al. Trial of early nifedipine in acute myocardial infarction: the TRENT study. BMJ 1986;293:1204-8.
90. Branagan JP, Walsh K, Kelly P, et al. Effect of early treatment with nifedipine in suspected acute myocardial infarction. Eur Heart J 1986;7:859-65.
91. Gottlieb SO, Becker LC, Weiss JL, et al. Nifedipine in acute myocardial infarction: an assessment of left ventricular function, infarct size, and infarct expansion: a double blind, randomised, placebo controlled trial. Br Heart J 1988;59:411-8.
92. Walker LJE, MacKenzie G, Adgey AAJ. Effect of nifedipine on enzymatically estimated infarct size in the early phase of acute myocardial infarction. Br Heart J 1988;59:403-10.
93. Erbel R, Pop T, Meinetz T, et al. Combination of calcium channel blocker and thrombolytic therapy in acute myocardial infarction. Am Heart J 1988;115:529-38.
94. The SPRINT Study Group. The Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) II. Design, methods and results. Eur Heart J 1988;9:350.
95. Gibson RS, Boden WE, Therous P, et al. Diltiazem and reinfarction in patients with a non Q wave myocardial infarction: results of a double-blind, randomized, multicenter trial. N Engl J Med 1986;315:423-9.
96. Zannad F, Amor M, Karcher G, et al. Effect of diltiazem on myocardial infarct size estimated by enzyme release, serial thallium-201 single photon emission computed tomography and radionuclide angiography. Am J Cardiol 1988;61:1172-7.
97. Nicolau JC, Ramires JA, Maggioni AP, et al. Diltiazem improves left ventricular systolic function following acute myocardial infarction treated with streptokinase: The Calcium Antagonist in Reperfusion Study (CARES). Am J Cardiol 1996; 78:1049-52.
98. Theroux P, Gregoire J, Chin C, et al. Intravenous diltiazem in acute myocardial infarction: Diltiazem as adjunctive therapy to activase (DATA) trial. J Am Coll Cardiol 1998;32:620-8.
99. The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J 1984;5:516-28.
100. Crea F, Deanfield J, Crean P, et al. Effects of verapamil in preventing early postinfarction angina and reinfarction. Am J Cardiol 1985;55:900-4.
101. Bussman W, Seher W, Gruengras M. Reduction of creatinine kinase and creatinine kinase-MB indexes of infarct size by intravenous verapamil. Am J Cardiol 1984; 54:1224-30.
102. Furberg CD, Pasty BM, Meyer JV. Nifedipine: dose related increase in mortaltity in patients with coronary artery disease. Circulation 1995;92:1326-31.
103. Boden WE, Scheldewaert R, Walters EG, et al. Design of a placebo controlled trial of long acting diltiazem and aspirin versus aspirin alone in patients receiving thrombolysis with a first acute myocardial infarction. Am J Cardiol 1995; 75:1120-3.
104. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol 1990;66:779-85.
105. Zuanetti G, Latini R, Avanzini F, et al. Trends and determinants of calcium antagonist usage after acute myocardial infarction (the GISSI experience). Am J Cardiol 1996;78:153-7.
106. Califf RM, Tardiff BE, Pieper KS, et al. Use of calcium channel blockers in myocardial revascularization procedures. Am J Cardiol 1996;77:26D-31D.
107. Dorros G, Cowley M, Simpson J, et al. Percutaneous transluminal coronary angioplasty: report of complications from the National Heart, Lung and Blood Institute PTCA registry. Circulation 1983;67:723-30.
108. VanBenthuyesen K, McMurty I, Horwitz L. Reperfusion after acute coronary occlusion in dogs impairs endothelium dependent relaxation to acetylcholine and augments contractile reactivity in vitro. J Clin Invest 1987;79:265-74.
109. Babbitt DG, Perry JM, Forman MB. Intracoronary verapamil for reversal of refractory coronary vasospasm during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1988;12:1377-81.
110. Pianna RN, Palik GY, Moscussi M, et al. Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation 1994;89:2514-8.
111. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Catheterization and Cardiovascular Diagnosis 1996;39:113-8.
112. Pomerantz RM, Kuntz RE, Diver DJ, et al. Intracoronary verapamil for treatment of distal microvascular spasm following PTCA. Cathet Cardiovasc Diagn 1991; 24:283-5.
113. Hillegass WB, Ohman EM, Leimberger JD, et al. A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. Am J Cardiol 1994;73:835-9.
114. Corcos T, David PR, Val PG, et al. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1985;109:926-31.
115. Whitworth HB, Roubin GS, Hollman H, et al. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1986;8:1274-6.
116. Hoberg E, Dieta R, Frees U, et al. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis. Br Heart J 1994;71:254-60.
117. O'Keefe JH, Giorgi LV, Hartzler GO, et al. Effect of diltiazem on complications and restenosis after coronary angioplasty. Am J Cardiol 1991;67:373-6.
118. Unverdorben M, Kinkel B, Leucht M, et al. Reduction of restenosis after PTCA by diltiazem? Circulation 1992;86:I-53.
119. Tyberg JV, Massie BM, Botvinick EH, et al. The hemodynamics of coronary arterial stenosis. In: Rahimtoola S, editor. Coronary bypass surgery, cardiovascular clinics. Philadelphia: Davis; 1977. p. 74-81.
120. Maseri A. Medical therapy of chronic stable angina. Circulation 1990;8:2758-62.
121. Ruschitzka FT, Noll G, Luscher T. The endothelium in coronary artery disease. Cardiology 1997;8(suppl 3):3-19.
122. Kaufmann P, Vassalli G, Utzinger U, et al. Coronary vasomotion during dynamic exercise: influence of intravenous and intracoronary nicardipine. J Am Coll Cardiol 1995;26:624-31.
123. Krinkler DM. Calcium antagonists for chronic stable angina. Am J Cardiol 1987; 59:95B-100B.
124. Sandler G, Cayton GA, Thornycroft SG. Clinical evaluation of verapamil in angina pectoris. BMJ 1968;3:224-7.
125. Livelsy B, Catley PF, Cambell RC, et al. Double blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. BMJ 1973;1:375-8.
126. Johnson SM, Mauritson DR, Corbett JR, et al. Double blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am J Med 1981;71:443-51.
127. Sadick N, Tan ATH, Fletcher PJ, et al. A double-blind randomized trial of propranolol and verapamil in the treatment of angina of effort. Circulation 1982;66:574-9.
128. Frishman WH, Klein NA, Strom JA, et al. Superiority of verapamil to propranolol in stable angina pectoris: a double blind crossover trial. Circulation 1982; 66:574-9.
129. Subramanian VB, editor. Calcium antagonists in chronic stable angina pectoris. Amsterdam: Excerpta Medica; 1983. p. 97-116, 152-6, 217-29.
130. Findlay IN, MacLeod K, Gillen G, et al. A double blind placebo controlled comparison of verapamil, atenolol and their combination in patients with chronic stable angina pectoris. Br Heart J 1987;57:336-43.
131. Lynch P, Dargie H, Krinkler S, et al. Objective assessment of antianginal treatment: a double blind evaluation of propranolol, nifedipine and their combination. BMJ 1980;281:184-7.
132. Kenmure ACF, Scrunton JH. A double blind controlled trial of the antianginal efficacy of nifedipine compared with propranolol. Br J Clin Pract 1980;suppl 8:49-52.
133. Higginbotham MB, Morris KG, Coleman RE, et al. Comparison of nifedipine alone with propranolol alone for stable angina pectoris including hemodynamics at rest and during exercise. Am J Cardiol 1986;57:1022-8.
134. Uusitalo A, Arstila M, Bae EA, et al. Metoprolol, nifedipine and the combination in stable effort angina pectoris. Am J Cardiol 1986;57:733-7.
135. Findlay IN, MacLeod K, Ford M, et al. Treatment of angina pectoris with nifedipine and atenolol: efficacy and effect on cardiac function. Br Heart J 1986;55:240-5.
136. Shapiro W, Narahara KA, Kositis JB, et al. Comparison of atenolol and nifedipine in chronic stable angina pectoris. Am J Cardiol 1989;64:186-90.
137. Kawanishi DT, Reid CL, Morrison EC, et al. Response of angina and ischemia to longterm treatment in patients with chronic stable angina: a double blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol 1992;19:1380-9.
138. Borzak S, Fenton T, Glasser S, et al. Discordance between effects of anti-ischemic therapy on ambulatory exercise performance and anginal symptoms in patients with stable angina pectoris. J Am Coll Cardiol 1993;21:1605-11.
139. Hung J, Lamb EH, Connolly SJ, et al. The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double blind, randomized, and placebo controlled study. Circulation 1983:68;560-7.
140. Strauss WE, Parisi AF. Superiority of combined diltiazem and propranolol for angina pectoris. Circulation 1985;71:951-7.
141. Humen DP, O'Brien P, Purnes P, et al. Effort angina with adequate beta receptor blockade: comparison of diltiazem alone and in combination. J Am Coll Cardiol 1986;7:329-35.
142. Weiner DA, McCabe CH, Cutter SS, et al. The efficacy and safety of high dose verapamil and diltiazem in the long-term management of stable exertional angina. Clin Cardiol 1984;7:648-53.
143. Khurmi NS, Rafferty EB. Comparative effects of prolonged therapy with four calcium inion antagonists (diltiazem, nicardipine, tiadimil, and verapamil) in patients with chronic stable angina pectoris. Cardiovasc Drugs Ther 1980;1:461-91.
144. Camerini F, Angelino PF, Bobba P, et al. Nifedipine in angina pectoris - a multicenter clinical trial. In: Hashimoto K, Kimura E, Kobayashi T, editors. First International Nifedipine "Adalat" symposium. Tokyo: University of Tokyo Press; 1975. p. 260-7.
145. Mueller HS, Chahine RA. Interim report of multicenter double blind, placebo controlled studies of nifedipine in chronic stable angina pectoris. Am J Med 1981; 71:645-57.
146. Pepine CJ, Lambert CR. Usefulness of nicardipine for angina pectoris. Am J Cardiol 59;13J:1987.
147. Bernink PJLM, De Weerd P, Ten Café FJ, et al. An 8-week double-blind study of amlodipine and diltiazem in patients with stable exertional angina pectoris. J Cardiovasc Pharmacol 1991;17(Suppl 1):S53.
148. Singh S, Doherty J, Udhoji V, et al. Amlodipine versus nadolol in patients with stable angina pectoris. Am Heart J 1989;11:1137.
149. Ecklund LG, Ulvenstam G, Wallidius G, et al. Effects of felodipine versus nifedipine on exercise tolerance in stable angina pectoris. Am J Cardiol 1994;73 658-60.
150. Alpert JS, Bakx ALM, Braun S, et al. Antianginal and anitischemic effects of mibefridil in the treatment of patients with chronic stable angina. Am J Cardiol 1997;80:20C-26C.
151. Picca M, Azzolini F, Cereda A, et al. Comparison of the antianginal efficacy of four calcium antagonists and propranolol in stable angina pectoris. Eur J Clin Pharmacol 1989;37:325-31.
152. Frishman WH. Beta-adrenergic blockade in the treatment of coronary disease. In: Hurst JW, editor. Clinical essays on the heart. New York: McGraw-Hill; 1984. p. 84.
153. Savanitto S, Ardissimo D. Selection of drug therapy in stable angina pectoris. Cardiovasc Drugs Ther 1998;12:197-210.
154. Savanitto S, Ardissimo D, Ergstrup K, et al. Combined therapy with metoprolol and nifedipine in comparison with monotherapy in patients with stable angina pectoris: results of the International Multicenter Angina Exercise Study (IMAGE). J Am Coll Cardiol 1986;27:311-6.
155. Foale RA. Atenolol versus the fixed combination of atenolol and nifedipine in stable angina pectoris. Eur Heart J 1993;14:1369-74.
156. The TIBET Study Group. The Total Ischemic Burden European Trial TIBET: Effects of atenolol, nifedipine SR and their combination on the exercise test and total ischemic burden in 608 patients with stable angina. Eur Heart J 1996; 12:96-103.
157. Rosengren A, Hagman M, Pennert K, et al. Clinical course and symptomology of angina pectoris in a population study. Acta Med Scand 1986;220:117-21.
158. Specchia G, Ghio S. Pathophysiology, clinical presentation, and prognosis of angina pectoris. In: Ardissimo D, Opie LH, Savonitto S, editors. Drug evaluation in angina pectoris. Boston: Kluwer Academic; 1994. p. 3-11.
159. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
160. Hermanson B, Omenn GS, Kronmal RA, et al. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease: results from the CASS registry. N Engl J Med 1998:319:1365.
161. Herbert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild-moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993;153:578-81.
162. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study Group (4S). Lancet 1994;344:1383.
163. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-5.
164. Solomon AJ, Gersch BJ. Management of chronic stable angina: medical therapy, percutaneous transluminal coronary angioplasty, and coronary artery bypass surgery: lessons learned from the trials. Ann Intern Med 1998;128:216-23.
165. Gheorghiade M, Weiner DA, Chakko S, et al. Monotherapy of stable angina with nicardipine hydrochloride: double blind, placebo-controlled, randomized study. Eur Heart J 1989;10:695-701.
166. Thadani U, Zellner SR, Glasser S, et al. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine: a new second generation calcium channel blocker in angina pectoris. Circulation 1991;84:2398-408.
167. Scheidt S, Lewinter MM, Hermanovich J, et al. Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial. Am J Cardiol 1986;58:715-21.
168. Tzivoni D, Banai S, Botvin S, et al. Effects of nisoldipine on myocardial ischemia during exercise and during daily activity. Am J Cardiol 1991;69:1048-57.
169. Dargie HJ, Ford I, Fox KM, et al. Total Ischemic Burden European Trial (TIBET): effect of ischemia and treatment with atenolol, nifedipine SR, and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996; 17:104-12.
170. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol versus verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm. Eur Heart J 1996;17:76-81.
171. Pepine CJ, Abrahms J, Marks RG, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994;90:762-76.
172. Pepine CJ. Silent myocardial ischemia: definition, magnitude and scope of the problem. Cardiol Clin 1986;4:577-81.
173. Fleg JL, Gerstinblith G, Zonderman AB, et al. Prevalence and prognostic significance of exercise induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers. Circulation 1990; 81:428-36.
174. Pepine CJ. β blockers or calcium antagonists in silent ischemia? Eur Heart J 1993;14(suppl F): F7-F14.
175. Blackshear JL, Safford RE. Myocardial ischemia clinical syndromes: silent myocardial ischemia. In: Guiliani ER, Gersh BJ, McGoon MD, et al, editors. Mayo Clinic practice of cardiology. St Louis: Mosby; 1996. p. 1135-60.
176. Hedblad B, Juul-Moller S, Svensson K, et al. Increased mortality in men with ST segment depression during 24 hour ambulatory long term ECG recording. Eur Heart J 1989;10:149-58.
177. Bonow RO, Lacharach SL, Green MV, et al. Prognostic implications of symptomatic versus asymptomatic (silent) myocardial ischemia induced by exercise in mildly symptomatic and in asymptomatic patients with angiographically documented coronary artery disease. Am J Cardiol 1987;60:778-83.
178. Narins CR, Wojiech Z, Moss AJ, et al: Clinical implications of silent versus symptomatic exercise induced myocardial ischemia in patients with stable coronary disease. J Am Coll Cardiol 1997;29:756-63.
179. Conn PF, Lawson WE. Effect of nifedipine on out of hospital silent myocardial ischemia in asymptomatic men with coronary artery disease. Am J Cardiol 1988; 61:908-10.
180. Mulcahy D, Cunningham D, Crean P, et al. Circadian variation of total ischemic burden and its alteration with antianginal agents. Lancet 1988;2:755-8.
181. Deanfield JE for the CAPE Investigators. Amlodipine reduces the total ischemic burden of patients with coronary diasease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE) trial [abstract]. J Am Coll Cardiol 1994;23:53A.
182. Mulcahy D, Purcell H, Sparrow J, et al. Effects of amlodipine versus diltiazem on morning peak in myocardial ischemic activity in angina pectoris. Am J Cardiol 1993;72:1203-6.
183. Subramanian VB, Bowles MJ, Khourmi NS, et al. Rationale for the choice of calcium antagonists in chronic stable angina: an objective double-blind, placebo-controlled comparison of nifedipine and verapamil. Am J Cardiol 1982;50:1173-9.
184. Singh N, Mironov D, Goodman S, et al: Treatment of silent ischemia in unstable angina: a randomized comparison of sustained release verapamil versus metoprolol. Clin Cardiol 1995;18:653-8.
185. Davies RF, Habibi H, Klinke WP, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. J Am Coll Cardiol 1995;25:619-25.
186. Deedwania PC, Carbajal EV, Nelson JR, et al. Anti ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent ischemia. J Am Coll Cardiol 1991;17:963-9.
187. Stone PH, Gibson RS, Glasser SP, et al. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients
188. Prinzmetal M, Kennamer R, Merliss R, et al. Angina pectoris: A variant form of angina pectoris. Am J Med 1959;27:375-88.
189. Stone PH. Calcium antagonists for Prinzmetal's variant angina, unstable angina and silent myocardial ischemia: therapeutic tool and probe for identification of pathophysiologic mechanisms. Am J Cardiol 1987;59:101B-115B.
190. Rosenthal SJ, Ginsburg R, Lamb IH, et al. Efficacy of diltiazem for control of symptoms of coronary arterial spasm. Am J Cardiol 1980;46:1027-32.
191. Pepine CJ, Feldman RL, Whittle J, et al. Effect of diltiazem in patients with variant angina: a randomized double blind trial. Am Heart J 1981;101:719-25.
192. Schroeder JS, Feldman RL, Giles TD,. Multiclinic controlled trial of diltiazem for Prinzmetal's variant angina. Am J Med 1982;72:227-32.
193. Tilmant PY, LaBlance JM, Thieuleux FA, et al. Detrimental effect of propranolol in patients with coronary arterial spasm countered by combination with diltiazem. Am J Cardiol 1983;52:230-3.
194. Previtali M, Salerno J, Tavazzi L, et al. Treatment of angina at rest with nifedipine: a short-term controlled study. Am J Cardiol 1980;45: 825-30.
195. Ginsburg R, Lamb IH, Schroeder JS, et al. Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm. Am Heart J 1982;103:44-8.
196. Hill JA, Feldman RL, Pepine CJ, et al. Randomized double-blind comparison of nifedipine and isosorbide dinitrate in patients with coronary arterial spasm. Am J Cardiol 1982;49:431-8.
197. Parodi O, Maseri A, Simonetti I. Management of unstable angina by verapamil: a double-blind crossover study in CCU. Br Heart J 1979;41:167-74.
198. Johnson SM, Mauritson DR, Willerson JT, et al. A controlled trial of verapamil for Prinzmetal's variant angina. N Engl J Med 1981;304:862-6.
199. Capucci A, Brachetti D, Carini G, et al. Propranolol versus verapamil in patients with unstable angina. In: Zanchetta A, Krinkler DM, editors. Calcium antagonism in cardiovascular therapy. Experience with verapamil. Amsterdam: Excerpta Medica; 1981. p. 198-205.
200. Parodi O, Simonetti I, Michelassi C, et al. Comparison of verpamil and propranolol therapy for angina pectoris at rest: a randomized multiple crossover controlled trial in the coronary care unit. Am J Cardiol 1989;57:899-906.
201. Waters DD, Theroux P, Szlachnic J, et al. Provocative testing with ergonovine to assess the efficacy of treatment with nifedipine, diltiazem, and verapamil in variant angina. Am J Cardiol 1981;48:123-30.
202. Schroeder JS, Lamb IH, Bristow MR, et al. Prevention of cardiovascular events in variant angina by long-term diltiazem therapy. J Am Coll Cardiol 1983;1:1507-11.
203. Previtali M, Salerno J, Tavazzi L, et al. Treatment of angina at rest with nifedipine: a short-term controlled study. Am J Cardiol 1980;45:825-30.
204. Schick EC, Liang C, Heupler FA, et al. Randomized withdrawal from nifedipine: placebo-controlled study in patients with coronary artery spasm. Am Heart J 1982;104:690-7.
205. Gelman JS, Feldman RL, Sio HE, et al. Nicardipine for angina pectoris at rest and coronary arterial spasm. Am J Cardiol 1985;56:232-6.
206. Chahine RA, Feldman RL, Giles TD, et al. Randomized placebo-controlled trial of amlodipine in vasospastic angina. J Am Coll Cardiol 1993;21:1365-70.
207. Ardissino D, Savonitto S, Mussini A, et al. Felodipine (once daily) versus nifedipine (four times daily) for Prinzmetal's angina pectoris. Am J Cardiol 1991; 68:1587-92.
208. Ginsburg R, Bristow MR, Harrison DC, et al. Studies with isolated human coronary arteries: some general observations, potential mediators of spasm, role of calcium antagonists. Chest 1980;78(suppl 1):180-6.
209. Lombardi M, Morales C, Michelassi E, et al. Efficacy of isosorbide 5-mononitrate versus nifedipine in preventing spontaneous and ergonovine-induced myocardial ischaemia: a double-blind, placebo-controlled study. Eur Heart J 1993;14:845-51.
210. Robertson D, Alastair JJW, Vaughn WK, et al. Exacerbation of vasotonic angina pectoris by propranolol. Circulation 1982;65:281-5.
211. Bory M, Benichou M, Franck R, et al. The ergometrine test in evaluation of the effects of verapamil and propranolol in vasospastic angina. In: Zanchetti A, Krikler DM, editors. Calcium antagonism in cardiovascular therapy. Experience with Verapamil. Amsterdam: Excerpta Medica; 1981. p. 198-205.
212. Yasue H, Omote S, Takizawa A, et al. Exertional angina pectoris caused by coronary arterial spasm: effect of various drugs. Am J Cardiol 1979;43:647-52.
213. Yasue H, Takizawa A, Nagao M, et al. Long-term prognosis for patients with variant angina and influential factors. Circulation 1988;78:1-9.
214. Hlatky MA, Cotungo HE, Mark DB, et al Trends in physician management of uncomplicated acute myocardial infarction, 1970-1978. Am J Cardiol 1988;61:515-8.
215. Leitch JW, McElduff P, Dobson A, et al. Outcome with calcium channel antagonists after myocardial infarction: a community based study. J Am Coll Cardiol 1988;31:111-7.
216. Ishikawa K, Nakai S, Takenaka T, et al. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Circulation 1997;95:2368-73.
217. Koenig W, Lowe H, Lewis M, et al. Long term survival after myocardial infarction: relationship with thrombolysis and discharge medication - results of the Augsberg myocardial infarction follow up study 1985-1993. Eur Heart J 1996;17:1199-206.
218. The Israeli SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): a randomised interventional trial of nifedipine in patients with acute myocardial infarction Eur Heart J 1988;9:354-64.
219. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-93.
220. Hansen JF, Hagerhup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Am J Cardiol 1997;79:738-41.
221. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the Calcium Antagonist Reinfarction Italian Study (CRIS). Am J Cardiol 1996:77:365-9.
222. Goodman S, Hill C, Bata I, et al. PROTECT (Prospective Reinfarction Outcomes in the Thrombolytic Era Cardizem CD Trial): a randomized, double-blind clinical trial of diltiazem versus atenolol in secondary prophylaxis post non-Q wave myocardial infarction. Can J Cardiol 1996;12:1183-90.
223. Viscoli CM, Horowitz RI, Singer BH. Beta-blockers after myocardial infarction: influence of first year clinical course on long term effectiveness. Ann Intern Med 1993;118:99-105.
224. Miller DB. Secondary prevention for ischemic heart disease. Arch Intern Med 1997;157:2045-52.
225. Gibson RS, Boden WE. Caclium channel antagonists: friend or foe in postinfarction patients. Am Heart J 1996;9:172S-176S.
226. Zuanetti G, Latini R, Avanzini F, et al. Trends and determinants of calcium antagonist usage after acute myocardial infarction (the GISSI experience). Am J Cardiol 1996;78:153-7.
227. Clinical practice guidelines. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. AHPCR publication no 940612; June 1994. p. 11-23.
228. Smith WM. Epidemiology of congestive heart failure. Am J Cardiol 1985;55:3A-8A.
229. Dong R, Liu P, Butany J, et al. Verapamil ameliorates the clinical and pathological course of murine myocarditis. J Clin Invest 1992;90:2022-30.
230. Figulla HR, Vetterlien F, Glaubitz M, et al. Inhomogenous capillary flow and its prevention by verapamil and hydralazine in the cardiomyopathic Syrian hamster. Circulation 1987;75:1058-64.
231. Pfeffer MA, Braunwald E, Moye L, et al. Effect of captopril in mortalitiy and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
232. The Acute Infarction Ramipril Efficacy Study Investigators. Effect of Ramipril in mortaltiy and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
233. Kober L, Torp-Petersen C, Carlsen J, et al. A clinical trial of angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
234. Ambrosioni E, Borghi C, Magnani B, et al. The effect of angiotensin converting enzyme inhibitor zofenopril in mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
235. Agostini PG, DeCesare N, Doria E, et al. Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy. Br Heart J 1986;55:391-9.
236. Elkayam U, Amin J, Mehra A, et al. A prospective randomized, double-blind, crossover study to compare the efficacy of chronic nifedipine therapy with that if isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954-61.
237. Elkayam U. Calcium channel blockers in heart failure. Cardiology 1998;89:38-46.
238. Kostis JB, Lacy CR, Cosgrove NM, et al. Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. Am Heart J 1997;133:550-7.
239. Gheorghiade M, Benatar D, Konstam MA. Pharmacotherapy for systolic dysfunction: a review of the randomized clinical trials. Am J Cardiol 1997;80:14H-27H.
240. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335:1107-14.
241. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-Heft III. Circulation 1997;96:856-63.
242. Figulla HR, Gietzen F, Uwe Z, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy: results of the diltiazem in dilated cardiomyopathy trial. Circulation 1996;94:346-52.
243. Figulla HR, Von Rechenberg J, Wiegand V, et al. Beneficial effects of long-term diltiazem treatment in dilated cardiomyopathy. J Am Coll Cardiol 1989;13:653-8.
244. Levine TB for the MACH 1 investigators. The design of the mortality assessment in congestive heart failure trial (MACH 1 mibefridil). Clin Cardiol 1997;20:320-6.
245. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995;26:1565-74.
246. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management. Ann Intern Med 1992;117:502-10.
247. Gaasch WH, Levine HJ, Quinones MA, et al. Left ventricular compliance: mechanisms and clinical implications. Am J Cardiol 1976;38:645-53.
248. Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med 1991;325:1557-64.
249. Grossman W, McLaurin WT. Diastolic properties of the left ventricle. Ann Intern Med 1976;84:316-26.
250. Ruzumna P, Gheorghiade M, Bonow RO. Mechanisms and management of heart failure due to diastolic dysfunction. Curr Opin Cardiol 1996;11:269-75.
251. Lakatta EG, Yin FC. Myocardial aging: function alterations and related cellular mechanisms. Am J Physiol 1982;242:H927-H941.
252. Capasso JM, Malhotra A, Remily RM, et al. Effects of age on mechanical and electrical performance of rat myocardium. Am J Physiol 1983;245:H72-H81.
253. Arrighi JA, Dilsizian V, Perrone-Filardi P, et al. Improvement in age related impairment in left ventricular diastolic filling with verapamil in the normal human heart. Circulation 1994;90:213-9.
254. Cheng CP, Petterson K, Little WC. Effects of felodipine on left ventricular systolic and diastolic performance in congestive heart failure. J Pharmacol Exp Ther 1994;271:1409-17.
255. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol 1979;43:1242-4.
256. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958;20:1-8.
257. St John Sutton MG, Lie JT, Anderson KR, et al. Histopathological specificity of hypertrophic cardiomyopathy: myocardial fibre disarray and myocardial fibrosis. Br Heart J 1980;44:433-44.
258. Maron BJ, Wolfson JK, Epstein SE, et al. Intramural (small vessel) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;8:545-7.
259. Louie EK, Edwards LC. Hypertrophic cardiomyopathy. Prog Cardiovac Dis 1994; 36:275-308.
260. Maron BJ, Bonow RO, Cannon RO, et al. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology and therapy [second of two parts]. N Engl J Med 1987;316:844-52.
261. Maron BJ, Bonow RO, Cannon RO, et al. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology and therapy [first of two parts]. N Engl J Med 1987;316:780-9.
262. Anderson DM, Raff GL, Ports TA, et al: Hypertrophic obstructive cardiomyopathy: effects of acute and chronic administration of verapamil on left ventricular systolic and diastolic function. Br Heart J 1984;51:523-9.
263. Hanrath P, Mathey DG, Kremer P, et al. Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy. Am J Cardiol 1980;45:1258-64.
264. Bonow RO, Rosing DR, Bacharach SL, et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 1981;64:787-96.
265. Bonow RO, Frederick TM, Bacharach SL, et al. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. Am J Cardiol 1983; 51:1386-91.
266. Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short and long term effects. Circulation 1985;72:853.
267. Rosing DR, Idanpaan-Heikkila U, Maron BJ, et al. Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. Am J Cardiol 1985;55(Suppl B):185B-195B.
268. Toshima H, Koga Y, Nagata H, et al. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy, double blind crossover study. Jpn Heart J 1986;27:701-15.
269. Udelson JE, Bonow RO, O'Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic obstructive cardiomyopathy. Circulation 1989;79:1052-60.
270. Rosing DR, Kent KM, Borer JS, et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation 1979;60:1201-7.
271. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981;64:437-41.
272. Frishman WH, LeJemtel T. Electropharmacology of calcium channel antagonists in cardiac arrhythmias. Pace 1982;5:402.
273. Frishman WH. Calcium channel blockers. In: Frishman WH, Sonnenblick EH, editors. Cardiovascular pharmacotherapeutics. New York: McGraw Hill; 1997. p. 101-30.
274. Benjamin FJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population based cohort: the Framingham heart study. JAMA 1994;271:840-4.
275. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-8.
276. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306:1018-22.
277. Blitzer M, Costeas C, Kassotis J, et al. Rhythm management in atrial fibrillation-with a primary emphasis in pharmacological therapy: part I. PACE 1998;21:590-602.
278. Talajic M, Nattel S. Frequency dependent effects of calcium antagonists on atrioventricular conduction and refractorines demonstration and characterization in anesthetized dogs. Circulation 1986;74:1156-67.
279. Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter: the diltiazem-atrial fibrillation/flutter study group. J Am Coll Cardiol 1984;4:105-10.
280. Ellenbogen KA, Dias VC, Cardello FP, et al. Safety and efficacy of intravenous diltiazem in atrial fibrillation or flutter. Am J Cardiol 1995;75:45-9.
281. Opie LH, Frishman WH, Thadani Y. Calcium channel antagonists (calcium entry blockers). In: Opie LH, editor. Drugs for the heart. 4th ed. Philadelphia: WB Saunders; 1995. p. 50-82.
282. Viskin S, Baron HB, Olgin JE, et al. The treatment of atrial fibrillation: pharmacologic and nonpharmacologic strategies. Curr Prob Cardiol 1997;22:39-108.
283. Suttorp MH, Kingma JH, Lie-A-Huen L, et al. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1995;75:693-7.
284. Roth A, Harrison E, Mitani G, et al. Efficacy and safety of medium and high dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986;73:316-24.
285. Brignole M, Menozzi C. Control of rapid heart rate in patients with atrial fibrillation: drugs or ablation? PACE 1996;19:348-56.
286. Schwartz J, Keefe D, Kates D, et al. Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation. Circulation 1982;65:1163-70.
287. Lang R, Klein H, Weiss E, et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 1983;83:491-9.
288. Pandis I, Monganroth H, Baessler C. Effectiveness and safety of oral verapamil to control exercise induced tachycardia in patients with atrial fibrillation receiving digitalis. Am J Cardiol 1987;52:1197-201.
289. Lang R, Klein H, Di Segni E, et al. Verapamil improves exercise capacity in chronic atrial fibrillation: double blind crossover study. Am Heart J 1983;105:820-4.
290. Steinberg J, Katz R, Bren G, et al. Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise. J Am Coll Cardiol 1987;9:405-11.
291. Maragno E, Santostasi G, Gaion R, et al. Low and medium dose diltiazem in chronic atrial fibrillation: comparison with digoxin and correlation with drug plasma levels. Am Heart J 1988;116:385-92.
292. Atwood E, Myers J, Sullivan M, et al. Diltiazem and exercise performance in patients with chronic atrial fibrillation. Chest 1988;92:20-5.
293. Lewis R, Laiing E, Moreland T, et al. A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. Eur Heart J 1988;9:279-83.
294. Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990;16:86-90.
295. Schwartz J, Keefe D, Kates D, et al. Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation. Circulation 1982; 65:1163-70.
296. Basta M, Klein GJ, Yee R, et al. Current role of pharmacologic therapy for patients with paroxysmal supraventricular tachycardia. Cardiol Clin 1997;15:587-97.
297. DiMarco JP, Miles W, Akhatar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Ann Intern Med 1990;113:104-10.
298. Goldberg IF, Lewis WR, Dias VC, et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol 1994;74:884-9.
299. Gulamhusein S, Ko P, Carruthers SG, et al: Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation 1982;65:348-54.
300. Mauritson DR, Winniford MD, Walfer WS, et al. Oral verapamil for paroxysmal supraventricular tachycardia: a long term, double blind, randomized trial. Ann Intern Med 1982;96:409.
301. Behassen B, Rotmensch HH, Laniado S. Response of recurrent sustained ventricular tachycardia to verapamil. Br Heart J 1981;46:679-82.
302. Lin L, Conti JB, Curtis AB. Termination and suppression of idiopathic left ventricular tachycardia by diltiazem. Clin Cardiol 1997;20:890-3.
303. Chevalier P, Dacosta A, DeFaye P, et al. Arrhythmic cardiac arrest due to isolated coronary artery spasm: long-term outcome of seven resuscitated patients. J Am Coll Cardiol 1998;31:57-61.
304. Manolio TA, Cutler JA, Furberg CD, et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995;155:829-37.
305. Alderman M, Cohen H, Roque R, et al. Long and short acting calcium channel antagonists differ with regard to cardiovascular outcomes in hypertensive patients. Lancet 1997;349:585-6.
306. Michels KB, Rosner BA, Manson JE, et al. Prospective study of calcium channel blocker use, cardiovascular disease, and total mortality among hypertensive women: the nurses' health study. Circulation 1998;97:1540-8.
307. Stason WB, Schmid CH, Niedzwiecki D, et al. Safety of nifedipine in patients with hypertension: a meta-analysis. Hypertension 1997;30:7-14.
308. Furberg CD, Pahor M, Patsy BM. The unnecessary controversy. Eur Heart J 1996;17:1142-7.
309. Durham ACH, Walton JM. Calcium ions and the control of proliferation in normal and cancer cells. Biosci Rep 1982;2:15-30.
310. Whitfield JF. Calcium signals and cancer. Crit Rev Oncog 1992;3: 55-90.
311. Martin SJ, Green DR. Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol 1995;18:137-53.
312. Trump BF, Berezesky IK. Calcium-mediated cell injury and cell death. FASEB J 1995;9:219-28.
313. Carson DA, Riberio JM. Apoptosis and disease. Lancet 1993;341:1251-4.
314. Mountz JD, Wu J, Cheng J, et al. Autoimmune disease: a problem of defective apoptosis. Arthritis Rheum 1994;37:1415-20.
315. Isner JM, Kearney M, Bortman S, et al. Apoptosis in human atherosclerosis and restenosis. Circulation 1995;91:2703-11.
316. Pahor M, Guralnik JM, Salvie ME, et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996;9:695-9.
317. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996;348:493-7.
318. Jick H, Jick S, Derby LE, et al. Calcium channel blockers and risk of cancer. Lancet 1997;349:525-8.
319. Olsen JH, Sorensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997;29:1091-4.
320. Fitzpatrick AL, Daling JR, Furberg C, et al. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997;80:1438-47.
321. Trenkwalder P, Ruland D, Stender M, et al. Prevalence, awareness, treatment and control of hypertension in a population over the age of 65: results from the Stanberg Study in Epidemiology of Parkinsonism and Hypertension in the Elderly (STEPHY). J Hypertens 1993;12:709-16.
322. Hole DJ, Gillis CR, McCallum IR, et al. Cancer risk of hypertensive patients taking calcium channel antagonists. J Hypertens 1998;16:119-24.
323. Braun S, Boyko V, Behar S, et al. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. J Am Coll Cardiol 1998;31:804-8.
324. Reference deleted by author.
325. Reference deleted by author.
326. Reference deleted by author.
327. Messerli FH, Grossman E. Do calcium channel antagonists increase the risk for malignancies? J Am Coll Cardiol 1998;31:809-10.
328. Textor SC, Taler SJ, Canzanello VJ, et al. Cancer after liver transplantation (TX): excess risk associated with calcium blocker administration? [abstract]. Am Heart J 1997;10:199A-214A.
329. Konrad-Dalhoff I, Baunack AR, Ransch KD, et al. Effect of the calcium channel antagonists nifedipine, nitrendipine, nimodipine and nisoldipine on oesophageal motility in man. Eur J Clin Pharmacol 1991;41:313-6.
330. Pahor M, Guralik JM, Furberg CD, et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347:1061-5.
331. Pilotto A, Leandro G, Franceschi M, et al. Antagonism to calcium antagonists. Lancet 1996;347:1761-2.
332. Grodecki-De Franco P, Steinhubl S, Taylor P, et al. Calcium antagonist use and perioperative bleeding complications: an analysis of 5,157 patients. Circulation 1996;94:I-476.
333. Hynynen M, Kuitunen A, Salmenpera M. Surgical bleeding and calcium antagonists [letter, comment]. BMJ 1996;312:313.
334. Joint National Committee on detection, evaluation and treatment of high blood pressure. The sixth report of the joint national committee on detection and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
335. Chadda K, Goldstein S, Byington R, et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-10.